Wengel Kathryn E.'s most recent trade in Johnson & Johnson was a trade of 30,841 Employee Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Feb. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 30,841 | 30,841 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,903 | 1,903 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 96,673 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 2,393 | 94,280 (0%) | 0% | 156.7 | 375,007 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 90,909 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 89,602 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 1,212 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 91,036 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 480 | 90,429 (0%) | 0% | 156.7 | 75,221 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 223 | 89,379 (0%) | 0% | 155.3 | 34,623 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 200 | 90,836 (0%) | 0% | 156.2 | 31,230 | Common Stock |
| Labcorp | Kathryn E. Wengel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 897 | 897 | - | - | Restricted Stock Unit | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 5,837 | 5,837 | - | - | Performance Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 32,762 | 115,027 (0%) | 0% | 100.1 | 3,278,166 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 32,762 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 26,076 | 88,951 (0%) | 0% | 153.1 | 3,992,757 | Common Stock |
| Labcorp | Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 0 | - | - | Restricted Stock Unit | |
| Labcorp | Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 3,236 (0%) | 0% | - | Common Stock | |
| Johnson & Johnson | E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 29,275 | 29,275 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,819 | 1,819 | - | - | Restricted Share Units | |
| Johnson & Johnson | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
| Johnson & Johnson | Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 82,598 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 333 | 82,265 (0%) | 0% | 157.8 | 52,564 | Common Stock |
| Johnson & Johnson | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 11,826 | 87,026 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn Wengel E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 11,826 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 7,066 | 81,947 (0%) | 0% | 157.4 | 1,112,188 | Common Stock |
| Johnson & Johnson | E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,987 | 89,013 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 35,638 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 09 Feb 2024 | 35,638 | 102,533 (0%) | 0% | 90.4 | 3,223,101 | Common Stock |
| Johnson & Johnson | Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.76 per share. | 09 Feb 2024 | 27,333 | 75,200 (0%) | 0% | 156.8 | 4,284,721 | Common Stock |
| Johnson & Johnson | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,971 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,971 | 67,904 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn Wengel E. | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,009 | 66,895 (0%) | 0% | 156.3 | 157,737 | Common Stock |
| Labcorp | E. Wengel Kathryn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 944 | - | - | Restricted Stock Unit | |
| Labcorp | E. Kathryn Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 2,292 (0%) | 0% | - | Common Stock | |
| Labcorp | Wengel Kathryn E. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 944 | 1,891 | - | - | Restricted Stock Unit | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Sale of securities on an exchange or to another person at price $ 160.00 per share. | 12 Jun 2023 | 12,465 | 65,933 (0%) | 0% | 160 | 1,994,400 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 32,317 | 32,317 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,839 | 83,289 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 4,891 | 78,398 (0%) | 0% | 162.0 | 792,391 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,953 | 1,953 | - | - | Restricted Share Units | |
| Labcorp | Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 1,345 (0%) | 0% | - | Common Stock | |
| Labcorp | Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 849 | - | - | Restricted Stock Unit | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,807 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,807 | 73,117 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 667 | 72,450 (0%) | 0% | 162.1 | 108,107 | Common Stock |
| Labcorp | Kathryn E. Wengel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 849 | 1,591 | - | - | Restricted Stock Unit | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 09 Nov 2022 | 16,410 | 87,720 (0%) | 0% | 72.5 | 1,190,381 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2022 | 16,410 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 173.42 per share. | 09 Nov 2022 | 16,410 | 71,310 (0%) | 0% | 173.4 | 2,845,773 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 16,410 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 10 Jun 2022 | 40,000 | 111,310 (0%) | 0% | 72.5 | 2,901,600 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 173.00 per share. | 10 Jun 2022 | 33,126 | 71,310 (0%) | 0% | 173.0 | 5,730,831 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 173.00 per share. | 10 Jun 2022 | 6,600 | 104,436 (0%) | 0% | 173.0 | 1,141,807 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 173.00 per share. | 10 Jun 2022 | 174 | 111,036 (0%) | 0% | 173 | 30,102 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 173.00 per share. | 10 Jun 2022 | 100 | 111,210 (0%) | 0% | 173 | 17,300 | Common Stock |
| Labcorp | Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 603 | 742 | - | - | Restricted Stock Unit | |
| Labcorp | Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 603 | 603 (0%) | 0% | - | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 30,214 | 30,214 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 10,386 | 76,009 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 10,386 | 990 | - | - | Performance Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.89 per share. | 14 Feb 2022 | 4,699 | 71,310 (0%) | 0% | 165.9 | 779,517 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,896 | 66,318 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,896 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,530 | 1,530 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 168.85 per share. | 14 Feb 2022 | 695 | 65,623 (0%) | 0% | 168.9 | 117,351 | Common Stock |
| Labcorp | Kathryn E. Wengel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 742 | 1,345 | - | - | Restricted Stock Unit | |
| Labcorp | Kathryn E. Wengel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 603 | 603 | - | - | Restricted Stock Unit | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 8,704 | 67,178 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 8,704 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.55 per share. | 12 Feb 2021 | 3,796 | 64,422 (0%) | 0% | 165.6 | 628,428 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,658 | 68,836 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,658 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.55 per share. | 12 Feb 2021 | 618 | 68,218 (0%) | 0% | 165.6 | 102,310 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 43,293 | 43,293 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 8,704 | 8,704 | - | - | Performance Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 1,971 | 1,971 | - | - | Restricted Share Units | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2020 | 8,238 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 153.53 per share. | 02 Sep 2020 | 8,238 | 58,419 (0%) | 0% | 153.5 | 1,264,755 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.20 per share. | 02 Sep 2020 | 8,238 | 66,657 (0%) | 0% | 62.2 | 512,404 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.37 per share. | 02 Sep 2020 | 7,877 | 74,534 (0%) | 0% | 65.4 | 514,919 | Common Stock |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2020 | 7,877 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 153.51 per share. | 02 Sep 2020 | 7,877 | 66,657 (0%) | 0% | 153.5 | 1,209,183 | Common Stock |